ESUR prostate MR guidelines 2012

This paper describes PI-RADS v1

NEJM prostate cancer MR lymph-node contrast

First paper, that describes the potential of Combidex to recognise small nodal metastases.

Updates on these papers

Combidex MRI in Prostate Cancer

MRI with a lymph-node-specific contrast agent as an
alternative to CT scan and lymph-node dissection in patients
with prostate cancer: a prospective multicohort study.


Full PIRADS v2 paper.

Synopsis of PI-RADS v2

Summary of PI-RADS v2 and beyond.

Web of Science

298 publications


see also 

Researcher-ID: D-3515-2009


Google Schoolar

Citation-index All     Since 2012
Citations 23092 13717
h-index 79 57
i10-index 211 176
 2 Top publications